Related Experiment Video
Updated: Jul 6, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Long-term follow-up of patients treated with ICD: benefit in patients with preserved left ventricular function
Folke Rönn1, Milos Kesek, Niklas Höglund
1Department of Cardiology, Heart Centre, Umeå University Hospital, Sweden.
Insights
Implantable cardioverter-defibrillators (ICDs) benefit patients with preserved heart function, offering life-saving therapy and good quality of life. Long-term outcomes show substantial survival benefits and low mortality in this population.
Area of Science:
- Cardiology
- Medical Devices
- Clinical Trials
Background:
- Major defibrillator trials often have limited follow-up periods.
- This limits understanding of long-term benefits in patients with preserved ejection fraction and advanced heart disease progression.
Purpose of the Study:
- To investigate the long-term outcomes of implantable cardioverter-defibrillators (ICDs) in an unselected patient population.
- To evaluate the effectiveness and safety of ICDs over an extended follow-up period.
Main Methods:
- A cohort of 124 consecutive patients receiving an ICD between 1993-2002 was followed for a median of 6.1 years.
- Data on heart disease, index arrhythmia, follow-up, and mortality were retrospectively collected from medical records.
Main Results:
- Crude mortality was 26% over the follow-up period.
- Heart failure was the primary cause of death (75%), particularly in patients with ejection fraction <35% (91% of deaths).
- An estimated 28% of patients received life-saving ICD therapy, with no significant relation between saved lives/complications and ejection fraction.
Conclusions:
- Implantable cardioverter-defibrillators (ICDs) are highly beneficial for patients with preserved left ventricular function.
- These patients experience substantial life-saving therapies, low mortality rates, and maintain a good quality of life.
Objective:
Most major defibrillator trials have short follow-up and may neither capture the benefit for those with preserved function nor the progressive nature of advanced heart disease. We intended to investigate the long-term outcome in an unselected population of patients treated with ICD.
Design:
We followed 124 consecutive patients that received an ICD during 1993-2002 at our institution for a median of 6.1 years. Information about heart disease, index arrhythmia, follow-up and death was extracted from medical records.
Results:
The crude mortality was 26% (32/124). One- and two-year mortality was 6% and 12%, estimated 5- and 10-year mortality 20% and 33%. The cause of death was heart failure in 75% of deaths. The ejection fraction was below 35% in 91% of the 32 patients who died. We estimated that 28% of the patients received lifesaving therapy. The relative number of saved lives and complications was not related to the ejection fraction.
Conclusion:
Patients with preserved left ventricular function are excellent candidates for ICD, with life-saving ICD therapies in a substantial proportion, low mortality and good quality of life.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Endocarditis III: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
